ABSTRACT
Objective To investigate the association between Hormone Replacement Therapy (HRT) or Combined Oral Contraception (COCP) use, and the likelihood of death in women with COVID-19.
Design A cohort study
Setting 465 general practices in England within the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) primary care database.
Population 1,863,478 women aged over 18 years
Methods We identified a cohort of women with COVID-19 from the computerised medical records of the RCGP RSC database. Mixed-effects logistic regression models were used to quantify the association between HRT or COCP use, and all-cause mortality among women with COVID-19 in unadjusted and adjusted models.
Results There were 5451 COVID-19 cases within the cohort. HRT was associated with a significantly lower likelihood of all-cause mortality in COVID-19 (adjusted OR 0.22, 95%□CI 0.05 to 0.94). There were no reported events for all-cause mortality in women prescribed COCPs. This prevented further examination of the impact of COCP.
Conclusions Women on HRT with COVID-19 had a lower likelihood of death. Further work is needed in larger cohorts to examine the association of COCP in COVID-19. Our findings support the current hypothesis that oestrogens may contribute a protective effect against COVID-19 severity.
Funding This study was funded by a School for Primary Care National Institute for Health Research grant (SPCR2014-10043).
Competing Interest Statement
The authors declare that no support from any organisation and no financial relationships have influenced the submitted work. SdeL has had investigator led funding from industry, and is member of two advisory boards, all funding are via his University. No other authors have any competing interests to declare.
Clinical Trial
n/a
Funding Statement
HDM is a National Institute for Health Research funded Academic Clinical Lecturer and has received NIHR SPCR funding for this project (SPCR2014-10043), and also acknowledges receipt of MRC funding for her COVID research (MR/V027778/1). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the UK National Institute for Health Research (NIHR) or the Department of Health and Social Care
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received approval from the Oxford- RCGP RSC study approval committee (RSC_0920) and the University of Southampton Research Ethics committee (56309) on the 6th May 2020.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available by direct request to the database https://www.rcgp.org.uk/clinical-and-research/our-programmes/research-and-surveillance-centre.aspx
https://www.rcgp.org.uk/clinical-and-research/our-programmes/research-and-surveillance-centre.aspx
